Organon (OGN) Fiscal Q2 Revenue Beats 1%
Organon (NYSE:OGN), a pharmaceutical company focused on women’s health, biosimilars, and established brands, released its fiscal Q2 2025 (ended June 30, 2025) results on August 5, 2025. The company reported GAAP revenue of $1.59 billion, above analyst expectations of $1.552 billion, and non-GAAP adjusted earnings per share (EPS) of $1.00, exceeding the $0.95 consensus estimate (non-GAAP). Despite these beats, both revenue and earnings (GAAP and non-GAAP) declined compared to fiscal Q2 2024, with net income (GAAP) falling to $145 million from $195 million in the prior-year period. The quarter’s results highlighted the company’s focus on new product growth and its ongoing challenges managing its legacy product portfolio.
Source: Analyst estimates provided by FactSet. Management expectations based on management's guidance, as provided in Q1 2025 earnings report.
Organon is a global pharmaceutical company that focuses on therapies in women’s health, biosimilars (which are follow-on versions of off-patent biologic drugs), and a portfolio of established brand medicines. Its products range from contraceptives to fertility treatments to biosimilar versions of major immunology and oncology drugs.
Source Fool.com
